Edition:
United States

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

55.50USD
15 Dec 2017
Change (% chg)

$0.77 (+1.41%)
Prev Close
$54.73
Open
$55.03
Day's High
$55.56
Day's Low
$54.85
Volume
7,626,181
Avg. Vol
1,612,878
52-wk High
$56.68
52-wk Low
$37.90

Latest Key Developments (Source: Significant Developments)

Quidel announces revised agreement for pending acquisition of Alere’s business
Monday, 18 Sep 2017 07:00am EDT 

Sept 18 (Reuters) - Quidel Corp :Quidel announces revised agreement for its pending acquisition of Alere’s B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter Analyzers.Quidel - ‍ previously announced transaction to purchase Triage Meterpro cardiovascular and toxicology assets from alere remains substantially unchanged​.Quidel-‍revised agreement provides co direct commercial responsibility after purchase for all sales globally of Alere's BNP assay unit run on Beckman Analyzers​.Quidel Corp - ‍ transactions will be funded through a combination of cash on hand and committed financing​.Quidel Corp - ‍total cash consideration for Alere's Triage MeterPro assets and beckman coulter bnp sales​ will now be up to $680 million.Quidel Corp - ‍ believe co is on track to close acquisition of Triage and BNP businesses within 30 days of Abbott's close of Alere acquisition​.Quidel- deal consideration of $680 million made of $400 million purchase price for triage business, $40 million in contingent consideration for eea bnp business.Quidel- deal consideration of $680 million also comprised of $240 million in deferred consideration for rest-of-world BNP business​.  Full Article

Abbott sets quarterly dividend of $0.265 per share
Thursday, 14 Sep 2017 12:30pm EDT 

Sept 14 (Reuters) - Abbott ::Sets quarterly dividend of $0.265 per share.  Full Article

Abbott Laboratories says ‍NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system
Wednesday, 13 Sep 2017 07:01am EDT 

Sept 13 (Reuters) - Abbott Laboratories :Abbott Laboratories - ‍NHS Business Services Authority approved listing on Drug Tariff for FreeStyle Libre system for people with diabetes using insulin​.Abbott Laboratories - ‍ from Nov. 1, 2017 FreeStyle Libre flash glucose monitoring technology will be available for reimbursement via NHS ​.  Full Article

Abbott initiates study of AMPLATZER device to correct congenital heart defect in newborns
Wednesday, 30 Aug 2017 11:56am EDT 

Aug 30 (Reuters) - Abbott Laboratories :Abbott initiates ground-breaking U.S. pivotal study of AMPLATZER device to correct common congenital heart defect in newborns.‍Study of AMPLATZER device​ will enroll approximately 50 patients at up to 10 centers across United States.  Full Article

U.S. FDA says has approved St. Jude medical’s firmware update ‍​
Tuesday, 29 Aug 2017 01:03pm EDT 

Aug 29 (Reuters) - U.S. Food and Drug Administration::U.S. FDA says has approved St. Jude medical’s firmware update ‍​.  Full Article

Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories ​
Wednesday, 16 Aug 2017 06:18am EDT 

Aug 16 (Reuters) - Enzo Biochem Inc ::Enzo Biochem says ‍a federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences, Inc. v. Abbott Laboratories - sec filing​.U.S. Court's order ‍denies summary judgment that U.S. Patent no. 8,097,405 is invalid for lack of written description.‍U.S. Court's order also granted summary judgment that U.S. Patent no. 8,097,405​ is invalid for lack of enablement.‍Enzo "disagrees" with court's decision, and is exploring options for review of decision​.  Full Article

Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc
Monday, 14 Aug 2017 08:00am EDT 

Aug 14 (Reuters) - Abbott Laboratories :Abbott announces extension of cash tender offer for all outstanding shares of series B convertible perpetual preferred stock of Alere Inc.Abbott Laboratories - ‍offer was previously scheduled to expire on Aug. 11, 2017 and will now expire, on Thursday, Aug. 31, 2017​.  Full Article

Abbott Laboratories says entered into term loan agreement with lenders
Monday, 31 Jul 2017 05:42pm EDT 

July 31 (Reuters) - Abbott Laboratories ::Abbott Laboratories - on july 31, co, entered into term loan agreement with lenders and Bank Of America, N.A., as administrative agent.Abbott Laboratories - loans will be made in a single borrowing and mature and be payable in full 5 years after date of such borrowing.Abbott Laboratories says term loan agreement provides co ability to borrow up to $2.8 billion on unsecured basis to finance Alere acquisition - sec filing.  Full Article

Abbott Q2 adjusted EPS $0.62 from continuing operations excluding items
Thursday, 20 Jul 2017 07:45am EDT 

July 20 (Reuters) - Abbott Laboratories ::Abbott reports second-quarter 2017 results.Q2 adjusted earnings per share $0.62 from continuing operations excluding items.Q2 gaap earnings per share $0.15 from continuing operations.Q2 earnings per share view $0.61 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $2.43 to $2.53 from continuing operations.Sees FY 2017 gaap earnings per share $1.03 to $1.13 from continuing operations.Q2 sales $6.6 billion versus I/B/E/S view $6.63 billion.Abbott Laboratories - ‍second-quarter worldwide sales of $6.6 billion increased 24.4 percent on a reported basis​.Abbott Laboratories qtrly total diagnostics sales $‍1,273​ million, up 3.8 percent on a reported basis.Abbott Laboratories - Q2 total vascular sales $731‍​ million, up 6.6 percent on a reported basis.Abbott Laboratories - qtrly total pediatric sales $‍​987 million, up 1.4 percent on a reported basis.Q2 total nutrition sales $1,731 million, down 0.6 percent on a reported basis.FY 2017 earnings per share view $2.47 -- Thomson Reuters I/B/E/S.Says ‍raises full-year 2017 EPS guidance range for continuing operations​.Abbott Laboratories - ‍sales growth in quarter impacted by purchasing patterns associated with implementation of new goods and services tax system in India​.  Full Article

Abbott, Bigfoot Biomedical enter deal to develop diabetes management systems
Thursday, 13 Jul 2017 07:30am EDT 

July 13 (Reuters) - Abbott Laboratories ::Abbott Laboratories and Bigfoot Biomedical enter agreement to develop and commercialize diabetes management systems.Abbott says financial terms of the agreement with Bigfoot are not being disclosed.Abbott says will supply glucose measurement sensors for all of Bigfoot's insulin delivery systems in U.S. as exclusive sensors for those systems.Bigfoot will develop and commercialize multiple systems using Abbott's freestyle libre sensor technology.In the U.S., freestyle libre system is currently pending approval by the U.S. Food and Drug Administration.  Full Article

BRIEF-Abbott Increases Quarterly Dividend To 28 Cents Per Share

* ABBOTT LABORATORIES - INCREASED COMPANY'S QUARTERLY COMMON DIVIDEND TO 28 CENTS PER SHARE FROM 26.5 CENTS PER SHARE Source text for Eikon: Further company coverage: